Prospective Study of a Cohort of Russian Nijmegen Breakage Syndrome Patients Demonstrating Predictive Value of Low Kappa-Deleting Recombination Excision Circle (KREC) Numbers and Beneficial Effect of Hematopoietic Stem Cell Transplantation (HSCT)

Autor: Elena Deripapa, Dmitry Balashov, Yulia Rodina, Alexandra Laberko, Natalya Myakova, Nataliia V. Davydova, Maria A. Gordukova, Dmitrii S. Abramov, Galina V. Pay, Larisa Shelikhova, Andrey P. Prodeus, Mikhail A. Maschan, Alexey A. Maschan, Anna Shcherbina

Publikováno v: Frontiers in Immunology, Vol 8 (2017)

BackgroundNijmegen breakage syndrome (NBS) is a combined primary immunodeficiency with DNA repair defect, microcephaly, and other phenotypical features. It predominantly occurs in Slavic populations that have a high frequency of carriers with the cau

Externí odkaz: https://doaj.org/article/1bdbf7cc32b040ae813011e012bc0489

Eltrombopag for the Treatment of Aplastic Anemia in Europe

Autor: Beatrice Drexler, Matyas Ecsedi, Etienne Lengline, Cora Knol, Paul Bosman, Boris Afanasiev, Alexey A. Maschan, Peter Dreger, Constantijn J.M. Halkes, Agostino Cortelezzi, Bernard Drenou, Gianluca Gaidano, Benedetto Bruno, Daniela Onofrillo, Edoardo Lanino, Drazen Pulanic, Ranka Serventi-Seiwerth, Alice Garnier, Per Ljungman, Francesca Bonifazi, Sabrina Giammarco, Olivier Tournilhac, Pietro Pioltelli, Alicia Rovo, Regis Peffault De Latour, Carlo Dufour, Jakob R. Passweg, for the EBMT SAA Working Party

Background Eltrombopag (ELT), an oral thrombopoetin-receptor agonist, has recently emerged as an encouraging and promising agent in acquired aplastic anemia. It has shown efficacy within clinical trials exploring its role in the first - line therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a54e6334515f5b4eff475e3e98dfa0eb
https://doi.org/10.1182/blood-2018-99-116363

Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Pediatric Leukemia

Autor: Maria Alyabeva, Larisa Shelikhova, Daria Shasheleva, Rimma Khismatullina, Svetlana Radygina, Anna Bogoyavlenskaya, Sergey Blagov, Olga Molostova, Svetlana Kozlovskaya, Irina Kalinina, Elena Kurnikova, Yakov Muzalevsky, Dmitriy Pershin, Alexander Popov, Olga Illarionova, Yulia Olshanskaya, Natalia Miakova, Dmitry Litvinov, Galina Novichkova, Alexey A. Maschan, Michael Maschan

Publikováno v: Blood. 132:2084-2084

Introduction The outcome hematopoietic stem cell transplantation (HSCT) in a cohort of children with chemorefractory leukemia is poor. The incidence of relapse exceeds 50% and survival varies from 10 to 40%. Additional attempts at remission induction

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cecd105a5a784304e35ff8a6c27bd771
https://doi.org/10.1182/blood-2018-99-116355

Alemtuzumab induction in pediatric kidney transplantation

Autor: N. Babenko, Dmitry Samsonov, Valery A Sandrikov, Alexey A. Maschan, A. Zokoev, Kaabak Mm

Publikováno v: Pediatric Transplantation

Recipient parenchymal lymphatic cells are crucial for direct and indirect pathways of allorecognition. We proposed that alemtuzumab, being infused several weeks pretransplant could eradicate peripheral lymphatic cells and promote donor-specific toler

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914803f6a36a35583aa6650755209e75
https://doi.org/10.1111/petr.12089

Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.

Autor: Kovach AE; Hematopathology, Division of Laboratory Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, CA, USA.; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Komova D; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Itov A; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Gaskova M; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Kalinina I; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Voronin K; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Rumiantseva Y; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Karachunskii A; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Maschan M; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Maschan A; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Novichkova G; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Olshanskaya Y; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Bhojwani D; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.; Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital Los Angeles, CA, USA., Raca G; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.; Cytogenomics, Division of Genomic Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, CA, USA., Zerkalenkova E; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2024 Aug 08, pp. 1-13. Date of Electronic Publication: 2024 Aug 08.